31.13MMarket Cap-2167P/E (TTM)
0.640High0.616Low53.07KVolume0.620Open0.635Pre Close33.22KTurnover0.23%Turnover RatioLossP/E (Static)49.52MShares1.57052wk High2.94P/B14.26MFloat Cap0.52052wk Low--Dividend TTM22.69MShs Float16.000Historical High--Div YieldTTM3.83%Amplitude0.520Historical Low0.626Avg Price1Lot Size
Icecure Medical Stock Forum
Near-term regulatory and operating catalysts have potential to accelerate adoption of ProSense® for treatment of early-stage, low risk breast cancer
Conference call to be held today at 10:00 am Eastern Time
CAESAREA, Israel, August 20, 2024 – IceCure Medical Ltd. (Nasdaq: ICCM) (“IceCure”, “IceCu...
IceCure Says The Study Concluded That 'Most Non-surgical Patients With Early-stage Breast Cancer Accepted Cryoablation When The Treatment Was Offered And That Cryoablation Is A Safe, Effective Alternative To Surgery And Well-tolerated As An Out-patient Procedure'
No comment yet